Phase 2 Alzheimer's drugs in development July 2019, by mechanism of action
Of the 72 drugs in phase two of development as of July 2019, 13 were focused on inhibiting amyloid production in the brain in order to hinder the growth of plaques. This statistic depicts the number of Alzheimer's drugs in phase two of clinical trials, by mechanism of action.